AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16632012
Drug: High-hemoglobin group
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-hemoglobin group (target 13 to 15 g/dL)
Trial: 16632012
Drug: Low-hemoglobin group
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-hemoglobin group (target 11 to 12 g/dL)
Trial: 20662805
Drug: Baclofen 30
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Baclofen 30 mg/d
Trial: 9364675
Drug: S-L* (yeast-derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-L* (yeast-derived recombinant hepatitis B virus vaccine containing surface antigen and selected preS1 and preS2 sequences)
Trial: 9364675
Drug: Engerix-B (vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Engerix-B (vaccine containing surface antigen alone)
Trial: 9364675
Drug: Both S-L*
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both S-L* and Engerix-B
Trial: 4065106
Drug: Atropine, 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine, 0.6 mg (given at peak effect of domperidone)
Trial: 21124125
Drug: Native subpectoral
RxNorm normalized name: Castanea sative leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Native subpectoral capsule (internal control)
Trial: 17015999
Drug: Sulbactam/ampicillin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulbactam/ampicillin therapy (6 g/day)
Trial: 17015999
Drug: Imipenem/cilastatin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatin therapy (1 g/day)
Trial: 12787040
Drug: Normal oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal oral mucosa (NOM)
Trial: 12787040
Drug: Friction hyperkeratosis
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Friction hyperkeratosis on OSF buccal mucosa (FHOSF)
Trial: 12787040
Drug: Oral leukoplakia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral leukoplakia on OSF buccal mucosa (OLOSF)
Trial: 9382431
Drug: Visual inspection
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visual inspection of the oral cavity and pharynx with flexible endoscopy and blue-toluidine staining
Trial: 1420743
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (5 mg by sublingual route 5 min before the meal)
Trial: 1420743
Drug: Sublingual nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual nifedipine (20 mg by sublingual route 30 min before the meal)
Trial: 3900458
Drug: TMS-19-Q.GC tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMS-19-Q.GC tablet (600 mg daily)
Trial: 3900458
Drug: Josamycin (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Josamycin (1,200 mg daily)
Trial: 27831987
Drug: Predictors included
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Predictors included age, lower‐most instrumented vertebra (LIV), pre‐operative sagittal vertical axis (SVA), upper‐most instrumented vertebra (UIV) implant type, UIV, pre‐operative pelvic tilt (PT), and pre‐operative pelvic incidence minus lumbar lordosis (PI-LL).
Trial: 25179849
Drug: Early aggressive
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early aggressive therapy
Trial: 16378115
Drug: Lidocaine 1
RxNorm normalized name: lidocaine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1 mg/kg administered before rebeat
Trial: 11833860
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g sodium oxybate
Trial: 11833860
Drug: 9 g
RxNorm normalized name: Publix Pen Needle 29 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 g sodium oxybate
Trial: 11833860
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g sodium oxybate
Trial: 7737713
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of 25 mg hydrochlorothiazide once daily for 1 month
Trial: 21958068
Drug: Amlodipine 10
RxNorm normalized name: amlodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 10 mg plus Telmisartan 80 mg
Trial: 16860426
Drug: Nonoxynol-9 vaginal
RxNorm normalized name: nonoxynol-9 Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoxynol-9 vaginal gel (52.5mg, 3.5%)
Trial: 23243245
Drug: AMP (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMP (5 g/kg of diet)
Trial: 21308291
Drug: Identical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical treatment using distilled water as cooling liquid
Trial: 11697754
Drug: Amlodipine (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (dosage not specified)
Trial: 7910272
Drug: Laparoscopic hernia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic hernia repair (group L) with transabdominal stapling of preperitoneal Prolene mesh.
Trial: 29141079
Drug: Ocriplasmin (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocriplasmin (125 μg, single intravitreal injection)
Trial: 25957056
Drug: Intravenous lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lysine acetylsalicylate (LA) 450 mg plus oral prasugrel 60 mg
Trial: 25957056
Drug: Oral aspirin
RxNorm normalized name: aspirin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral aspirin 300 mg plus prasugrel 60 mg
Trial: 19567309
Drug: Supplemental buccal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental buccal and lingual infiltrations of 2% lidocaine with 1:200,000 epinephrine
Trial: 19567309
Drug: Supplemental buccal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental buccal and lingual infiltrations of 4% articaine with 1:200,000 epinephrine
Trial: 9256139
Drug: CTVP (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTVP (cyclophosphamide 750 mg/m2, teniposide 75 mg/m2, prednisone 40 mg/m2/d for 5 days plus pirarubicin 50 mg/m2)
Trial: 9256139
Drug: CVP (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVP (cyclophosphamide 750 mg/m2, teniposide 75 mg/m2, prednisone 40 mg/m2/d for 5 days)
Trial: 30392575
Drug: 3 daily
RxNorm normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3 daily capsules of 200 mg DHA each (n=176)
Trial: 30392575
Drug: 3 daily
RxNorm normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3 daily capsules of vegetable oil without DHA (n=169)
Trial: 27109816
Drug: Extrafine glycopyrronium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extrafine glycopyrronium bromide (GB) 12.5, 25 or 50 μg twice daily (BID) plus beclometasone dipropionate plus formoterol fumarate (BDP/FF)
Trial: 27109816
Drug: Extrafine glycopyrronium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extrafine glycopyrronium bromide (GB) 25 μg BID plus beclometasone dipropionate plus formoterol fumarate (BDP/FF)
Trial: 27109816
Drug: Extrafine glycopyrronium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extrafine glycopyrronium bromide (GB) 50 μg BID plus beclometasone dipropionate plus formoterol fumarate (BDP/FF)
Trial: 27109816
Drug: Extrafine glycopyrronium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extrafine glycopyrronium bromide (GB) 12.5 μg BID
Trial: 27109816
Drug: Extrafine glycopyrronium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extrafine glycopyrronium bromide (GB) 25 μg BID
Trial: 27109816
Drug: Extrafine glycopyrronium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extrafine glycopyrronium bromide (GB) 50 μg BID
Trial: 22215473
Drug: Reduced-dose RCHOP
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced-dose RCHOP chemotherapy (375 mg/m² rituximab, 600 mg/m² cyclophosphamide, 30 mg/m² doxorubicin, 1 mg vincristine, and 40 mg prednisone)
Trial: 22215473
Drug: Reduced-dose RCHOP
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced-dose RCHOP chemotherapy
Trial: 18208828
Drug: Low-dose warfarin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose warfarin with aspirin
Trial: 16135834
Drug: Risedronate (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate (30 mg per day for 60 days)
Trial: 11812681
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% (2 mg/kg)
Trial: 11812681
Drug: Bupivacaine 0.2%
RxNorm normalized name: BUPivacaine 0.2%-NaCl 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.2% (2 mg/kg)
Trial: 10418698
Drug: D,L-fenfluramine hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D,L-fenfluramine hydrochloride (60 mg) after T-
Trial: 7428409
Drug: Controlled-release aminophylline
RxNorm normalized name: aminophylline Delayed Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release aminophylline plus routine inhaled salbutamol
Trial: 7428409
Drug: Controlled-release aminophylline
RxNorm normalized name: aminophylline Delayed Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release aminophylline and inhaled salbutamol on demand
Trial: 7428409
Drug: Controlled-release aminophylline
RxNorm normalized name: aminophylline Delayed Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release aminophylline plus inhaled salbutamol on need
Trial: 7428409
Drug: Oral salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral salbutamol plus routinely inhaled salbutamol
Trial: 11943957
Drug: Dioctahedral smectite
RxNorm normalized name: Dioctahedral smectite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dioctahedral smectite combined with hypotonic oral rehydration solution (Gastrolit)
Trial: 27749549
Drug: Group G
RxNorm normalized name: Prostaglandin group G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group G (mandibular angle approach)
Trial: 27749549
Drug: Group G
RxNorm normalized name: Prostaglandin group G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group G
Trial: 24424249
Drug: Ranibizumab PRN
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab PRN (after 6 months of sham treatment)
Trial: 24424249
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment followed by ranibizumab 0.5 mg PRN
Trial: 22212377
Drug: PUFA 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUFA 4 g daily for 12 weeks
Trial: 20339140
Drug: Long-acting octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting octreotide acetate (LAO) 30 mg via intramuscular injection, given 4-7 days before radiation and on day 22 of treatment.
Trial: 20339140
Drug: Placebo, given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, given 4-7 days before radiation and on day 22 of treatment.
Trial: 15323164
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy (at least one course)
Trial: 8675251
Drug: High insulinemia
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High insulinemia (287 pmol/L)
Trial: 1999687
Drug: Beta-carotene (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (10 mg daily for 3 months)
Trial: 1999687
Drug: Total intake
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intake of beta-carotene (diet + medication)
Trial: 6095660
Drug: ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ranitidine 150 mg taken orally at night for 12 months
Trial: 6095660
Drug: cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cimetidine 400 mg taken orally at night for 12 months
Trial: 15338805
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg of testosterone, intra-muscularly, every fourth week for 26 weeks
Trial: 8277078
Drug: SHU 508A
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SHU 508A (200 mg/ml in 5 ml, 200 mg/ml in 10 ml, 300 mg/ml in 5 ml, 300 mg/ml in 10 ml)
Trial: 2551411
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (5.4 g eicosapentaenoic acid and 3.6 g docosahexaenoic acid)
Trial: 786670
Drug: Nomifensin (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomifensin (average daily dose 84 mg)
Trial: 786670
Drug: Desimipramine (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desimipramine (average daily dose 76 mg)
Trial: 29308523
Drug: 100 g-force
RxNorm normalized name: ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY 19 g in 100 g TOPICAL STICK [Brut Arctic Force]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g-force
Trial: 29308523
Drug: 150 g-force
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 g-force
Trial: 29308523
Drug: 200 g-force
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 g-force
Trial: 23668634
Drug: Remogliflozin etabonate
RxNorm normalized name: Remogliflozin etabonate
DrugBank: Remogliflozin etabonate (DB12935)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remogliflozin etabonate (RE) 20 mg, 50 mg, 150 mg, 500 mg, or 1000 mg
Trial: 23668634
Drug: Remogliflozin etabonate
RxNorm normalized name: Remogliflozin etabonate
DrugBank: Remogliflozin etabonate (DB12935)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remogliflozin etabonate (RE) 50 mg and 500 mg
Trial: 20855554
Drug: Shockwave therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shockwave therapy (SWT) - 2500 impulses per session at 0.18 mJ/mm² energy flux density for 4 weeks
Trial: 20855554
Drug: Traditional conservative
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional conservative treatment (TCT) - nonsteroidal anti-inflammatory drugs, physiotherapy, and an exercise program for hamstring muscles for 4 weeks
Trial: 17766923
Drug: Metformin 850
RxNorm normalized name: metFORMIN 850 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 850 mg twice daily for 6 months
Trial: 17766923
Drug: Metformin in
RxNorm normalized name: Product containing metformin in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin in obese women
Trial: 11137806
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with cholesterol <4.7mmol/l (group 3)
Trial: 9505749
Drug: Bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.5% (5 ml infiltrated along the scrotal incision and 1 ml injected into the vas deferens)
Trial: 7881986
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (oral or intravenous)
Trial: 2119396
Drug: Sprinkle capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sprinkle capsules
Trial: 2119396
Drug: Sprinkle capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sprinkle capsules (fasting)
Trial: 2119396
Drug: Enteric-coated tablets
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated tablets (fasting)
Trial: 2119396
Drug: Sprinkle capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sprinkle capsules (nonfasting)
Trial: 322267
Drug: Tolfenamic acid
RxNorm normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolfenamic acid 600 mg administered as three divided doses with meals for one week.
Trial: 322267
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid 3 g administered as three divided doses with meals for one week.
Trial: 11152249
Drug: 100% oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% oxygen (4 L min(‐1))
Trial: 11152249
Drug: Air (21%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air (21% oxygen, 4 L min(‐1))
Trial: 9091710
Drug: Retrobulbar injection
RxNorm normalized name: LIDOCAINE HYDROCHLORIDE 40 mg in 1 mL RETROBULBAR INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrobulbar injection (prilocaine/etidocaine mixture)
Trial: 9091710
Drug: Retrobulbar injection
RxNorm normalized name: LIDOCAINE HYDROCHLORIDE 40 mg in 1 mL RETROBULBAR INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrobulbar injection
Trial: 1301126
Drug: Hospital-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital-based treatment (H)
Trial: 3905773
Drug: Methylphenidate (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (up to 60 mg/day)
Trial: 29699021
Drug: Ulinastatin 100,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulinastatin 100,000 u intravenous injection every 8 hours for 7 days
Trial: 29699021
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treated with hyperbaric oxygen and routine medical treatment
Trial: 23183990
Drug: Multimodal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal treatment program
Trial: 17785618
Drug: Sildenafil (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (25 to 75 mg orally 3 times daily)
Trial: 15932791
Drug: Pentoxifylline 400
RxNorm normalized name: pentoxifylline 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 400 mg four times a day
Trial: 17557
Drug: Penbutolol (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penbutolol (8 mg to 50 mg per day)
Trial: 27837709
Drug: Comprehensive geriatric
RxNorm normalized name: CATHETER,EXTERNAL CONVEEN #5120 GERIATRIC/PEDIATRIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive geriatric assessment (CGA) including medication assessment annually between 2004 and 2007
Trial: 3538753
Drug: Femoxetine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Femoxetine (200 mg increasing to 600 mg daily over 9 days)
Trial: 28532406
Drug: Vildagliptin/Metformin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin/Metformin therapy (n = 40)
Trial: 28532406
Drug: Metformin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin alone (n = 20)
Trial: 27128001
Drug: Ketoconazole (strong
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (strong CYP3A4 inhibitor)
Trial: 27128001
Drug: Azithromycin (weak
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (weak CYP3A4 inhibitor)
Trial: 27128001
Drug: Alisporivir (as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisporivir (as an inhibitor of CYP3A4)
Trial: 21146637
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and Simvastatin
Trial: 16934158
Drug: Fixed-dose artesunate-sulfamethoxypyrazine-pyrimethamine
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fixed-dose artesunate-sulfamethoxypyrazine-pyrimethamine (AS+SMP f) administered at 12-hour intervals for 24 hours
Trial: 16934158
Drug: Loose combination
RxNorm normalized name: loose wheat smut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loose combination of artesunate-sulfamethoxypyrazine-pyrimethamine (AS+SMP l) administered at 24-hour intervals for 3 days
Trial: 16934158
Drug: Both regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both regimens (AS+SMP f and AS+SMP l)
Trial: 10633973
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg/day for one week and 40 mg/day thereafter (group I)
Trial: 10633973
Drug: Sertraline 50
RxNorm normalized name: sertraline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 50 mg/day (group II)
Trial: 10633973
Drug: Fluoxetine (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (group I)
Trial: 10633973
Drug: Sertraline (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (group II)
Trial: 8607401
Drug: Quinapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (5 to 10 mg/day)
Trial: 8607401
Drug: Metoprolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (50 to 100 mg/day)
Trial: 1901181
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate tablets
Trial: 30586694
Drug: Macitentan 10
RxNorm normalized name: macitentan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macitentan 10 mg once daily for 16 weeks
Trial: 28765326
Drug: Azacitidine (AZA)
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine (AZA) monotherapy (75 mg/m2 × 7 days every 28 days)